Consultation on Proposal to Fund Lenvatinib for Kidney, Thyroid and Liver Cancers

Pharmac NZ are seeking feedback on a proposal to fund to lenvatinib, subject to eligibility criteria, for renal cell carcinoma (in combination with everolimus) as well as differentiated thyroid cancer, and advanced, unresectable hepatocellular carcinoma.